US regulatory status: approved.
pharma · Non-muscle invasive bladder cancer (NMIBC) · Low Grade Upper Tract Urothelial Carcinoma · TYRA
Tyra Biosciences
Tyra Biosciences drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Carlsbad, USA HQ
93 Employees
Public company Type
TYRA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carlsbad, USA
- Employees
- 93
- Programs
- 9
- Drugs
- 3
- Patents
- 17
Tyra Biosciences pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tyra Biosciences drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Tyra Biosciences in public FDA and regional records.
-
Development asset linked to Tyra Biosciences in public FDA and regional records.